Intensive chemotherapy for Philadelphia-chromosome-positive acute lymphoblastic leukaemia

Chilhood acute lymphoblastic leukaemia with the classic Philadelphia chromosome translocation is fatal in patients treated with chemotherapy alone. We report probable curses in three adolescents and one child who received extensively reinforced, early chemotherapy followed by rotational treatment wi...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 1994-02, Vol.343 (8893), p.331-332
Main Authors: Roberts, W.M., Rivera, G.K., Raimondi, S.C., Santana, V.M., Sandlund, J.T., Crist, W.M., Pui, C-H.
Format: Article
Language:English
Subjects:
Acute lymphoblastic leukemia
Adolescent
Adolescents
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Bone marrow
Bone marrow transplantation
Brain Neoplasms - drug therapy
Burkitt Lymphoma - drug therapy
Burkitt Lymphoma - genetics
Burkitt Lymphoma - mortality
Chemotherapy
Child
Child, Preschool
Chromosomes
Follow-Up Studies
Humans
Immunosuppressive agents
Leukemia
Leukocyte Count
Long bone
Medical sciences
Patients
Pharmacology. Drug treatments
Philadelphia Chromosome
Random Allocation
Remission
Remission Induction
Subgroups
Translocation
Transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chilhood acute lymphoblastic leukaemia with the classic Philadelphia chromosome translocation is fatal in patients treated with chemotherapy alone. We report probable curses in three adolescents and one child who received extensively reinforced, early chemotherapy followed by rotational treatment with pairs of non-cross-resistant drugs. The median duration of leukaemia-free survival in this subgroup is 6 5 years (range 6–8 years). The two patients with long-term bone marrow surveillance fro residual disease showed no evidence of the Philadelphia chromosome at 31 and 53 months post-remission. Such intensive chemotherapy is a reasonable option for patients who are not able to undergo bone marrow transplantation.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(94)91166-5